A dose-response analysis was conducted on relative risks (RRs) of incident MetS and individual MetS components (including hyperglycemia, abdominal obesity, hypertriglyceridaemia, low high-density lipoprotein cholesterol [HDL-C] and hypertension) caused by 5 units per liter (U/l) of ALT increments. The gene discussed is GPT; the disease is Hyperglycemia.